Study Findings from University of Miami Miller School of Medicine Advance Knowledge in Desmoid Tumor (Sorafenib treatment duration in desmoid tumors).

A recent study conducted by the University of Miami Miller School of Medicine examined the optimal duration of sorafenib treatment for desmoid tumors. Desmoid tumors are non-metastatic soft-tissue neoplasms that can cause significant morbidity. The study found that discontinuing sorafenib treatment before one year was associated with a higher risk of requiring further therapy within the following two years. However, most patients did not require additional therapy. The findings highlight the complexity of determining the optimal duration for sorafenib therapy and emphasize the importance of considering various factors such as side effects, symptom improvement, fertility planning, tumor cellularity, and shared decision-making between physicians and patients. [Extracted from the article]